US 4,863,743 AGrant
Controlled Release Potassium Chloride
Issue Date:1989-09-05
•12 Claims
Abstract
A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro pellets which then can be compressed into tablets. The tablets disintegrate rapidly in an aqueous environment thus assuring a more uniform dissolution of the active component as compared with other types of controlled release potassium chloride dosage formulations. The distribution of the potassium chloride micro pellets over a wide surface area in the gastrointestinal mucosa aids in reducing the risk of gastrointestinal lesions. The formation of the coated micro pellets which disperse quickly upon contact with aqueous environment allow for the repeated chronic oral administration of a relatively large dose of potassium chloride (20 mEq).
Metadata
Assignee
- Key Pharmaceuticals, Inc.
Inventors
- Charles Hsiao
- Chi T. Chou
Application Information
Application Number:US 8309817
Filing Date:1986-02-19
Priority Date:1985-02-19
Art Unit:125
Classifications
IPC:
A61K 932A61K 936
Field of Search:
424480;473;476;482;495;497;498
Patent Drawings
This patent does not have any drawings.
Description
Example 1
The potassium chloride crystals (30-50 mesh) were coated in a 6" Wurster fluidized bed column with 15% (w/w) of Ethocel.RTM. 10 and PEG 4500 E. (14:1 ratio). The Ethocel.RTM. type 10 and PEG 4500 E were dissolved in chloroform and methanol co-solvent system (4:1 ratio). The crystals were coated at 60.degree. C. inlet temperature. The spraying pressure was 1.5 bars and the spray speed was approximately 15ml per minute. Afterwards, 93% of the coated crystals, 6% of Avicel.RTM. PH101 (microcrystalline cellulose) and 1% of crospovidone (cross-linked polyvinylpyrrolidone) were mixed well and compressed into tablets with a Stokes DS 3 press, equipped with capsule-shape punches (0.34".times.0.873".times.0.086"). The dosage of the tablets was 20 mEq or 1500 mg KCl.
A second batch of potassium chloride crystals was coated with 15% (w/w) of Ethocel.RTM. type 100 and PEG 4500 E (14:1 ratio) and compressed into tablets which included the excipients indicated above. All the experimental procedures were the same as mentioned above, except the type of ethylcellulose used.
A dissolution study of the coated crystals (micro pellets) was performed in deionized water.
The following table is a summary of the dissolution test:
Example 2
The potassium chloride crystals (30-50 mesh size) were coated in a 6" Wurster fluidized bed column with 15% (w/w) of Ethocel.RTM. 10, Klucel.RTM. L.F. and Mg stearate (8.5:1:0.5 ratio). The Ethocel.RTM. 10 and Klucel.RTM. L.F. were dissolved in a chloroform and methanol co-solvent system. Magnesium stearate was then added to the polymer solution to form a suspension. The suspension was stirred by a lab stirrer throughout the coating process to avoid the sedimentation of magnesium stearate. The crystals were coated at 60.degree. C. inlet temperature. The spraying pressure was 1.5 bars and the spray speed is approximately 15 ml per minute. Afterwards, 93% of the coated crystals, 6% of Avicel.RTM. PH101 (microcrystalline cellulose) and 1% of crospovidone (crosslinked polyvinylpyrrolidone) are mixed well and compressed into capsule-shaped tablets. The dosage of the tablets was 20 mEq or 15 mg of KCl.
A second batch of potassium chloride crystals was coated with 15% (w/w) of Ethocel.RTM. 100, Klucel.RTM. L.F. and magnesium stearate (8.5:1:0.5 ratio) and compressed into tablets with the same excipients indicated above. All the experimental procedures were the same as mentioned above except the type of ethylcellulose used.
A dissolution study of the coated crystals and tablets was performed in deionized water.
The following table is a summary of the dissolution test:
In accordance with a preferred embodiment of the present invention potassium chloride tablets containing 1500mg of potassium chloride are prepared. The potassium crystals form about 68% to about 86.5% by weight of these tablets and are coated with ethylcellulose (preferably Ethocel.RTM. 100) in an amount in the range of 9 to 15% by weight based on the weight of the micro pellets formed with the potassium chloride crystals; 0.5 to 3% by weight of hydroxypropylcellulose based on the weight of the micro pellets; 0.5 to 2% by weight of magnesium stearate based upon the weight of the tablet; 3 to 10% by weight of microcrystalline cellulose based upon the weight of the tablet; 0.5 to 2% by weight crospovidone based upon the weight of the tablet.
Within each of these ranges it is particularly preferred for the 1500 mg tablets to include 79 weight percent of potassium chloride, 11.9% by weight of ethylcellulose (preferably Ethocel.RTM. 100), 1.4% by weight hydroxypropylcellulose, 0.7% by weight of magnesium stearate, 6% by weight of microcrystalline cellulose and 1% by weight of crospovidone.
In accordance with the present invention a clinical batch of 1500 mg tablets of potassium chloride were prepared. The tablets were comprised as shown in the following Table III.
Comparative Experiment
In order to demonstrate the safety of the present invention, a clinical study was carried out which compared potassium chloride tablets (20 mEq) produced in accordance with the present invention with four commercial products as follows: Slow-K.RTM. (a sugar-coated wax matrix tablets from Ciba); Micro-K Extencaps.RTM., (capsules of crystalline KCl particles coated with polymer from A. H. Robins); Kaon.RTM. Elixir (liquid potassium gluconate), and placebo.
In this particular investigator blinded study comparing the 20 mEq KCl tablets to 4 standard preparations in a dose of 80 mEq per day, no serious endoscopic lesions were found with the tablet of the present invention. Overall, the safety of the tablet was equal to or better than any of the comparative agents.
The present invention has been disclosed and described herein in what is considered to be its most preferred embodiments. It should be noted that variations may occur to those skilled in the art upon reading the present disclosure and that such variations are intended to come within the scope of the present invention.
Claims
What is claimed is:
1. A pharmaceutical dosage unit in tablet form for oral administration of potassium chloride, comprising; a plurality of coated potassium chloride crystals, the amount of potassium chloride being in the range of about 64% to about 86.5% by weight based on the total weight of the dosage unit; a coating material for the individual potassium chloride crystals, the coating material comprising ethylcellulose in the amount in the range of about 9% to about 15% by weight based on the total weight of the coated crystals and at least one member selected from hydroxypropylcellulose and polyethylene glycol in an amount in the range of about 0.5% to about 3% by weight based on the total weight of the coated crystals and said ethylcellulose has a viscosity greater than 40 cp.
2. A pharmaceutical dosage unit as claimed in claim 1, wherein the tablet is further comprised of magnesium stearate in an amount in the range of about 0.5% to 2.0% by weight based on the total weight of the tablet.
3. A pharmaceutical dosage unit as claimed in claim 2, wherein the tablet is further comprised of a microcrystalline cellulose in an amount in the range of about 3 to 10% by weight based on the total weight of the tablet.
4. A pharmaceutical dosage unit as claimed in claim 3, further comprising cross-linked polyvinylpyrolidone in an amount in the range of about 0.5 to about 2.0% by weight based on the total weight of the tablet.
5. A pharmaceutical dosage unit as claimed in claim 1, wherein the potassium chloride is in the form of crystals which have a mesh size in the range of about 30 to about 50 mesh.
6. A pharmaceutical dosage unit as claimed in claim 5, wherein the potassium chloride crystals have a mesh size of about 40 mesh.
7. A pharmaceutical dosage unit as claimed in claim 1, wherein the ethylcellulose has a viscosity of from 85 to 110 cp.
8. A pharmaceutical dosage unit as claimed in claim 1, wherein the member selected from hydroxypropylcellulose and polyethylene glycol is hydroxypropylcellulose.
9. A pharmaceutical unit as claimed in claim 1, wherein the member selected from hydroxypropylcellulose and polyethylene glycol is polyethylene glycol.
10. A method of providing potassium to a subject in need of potassium, comprising administering to the subject a therapeutically useful amount of potassium chloride in a dosage unit according to claim 1.
11. The method of claim 10, wherein the dosage unit is disintegrated in water or on an aqueous food prior to administration.
12. The pharmaceutical dosage unit in tablet form of claim 2 comprising: 68-86.5% by weight of coated potassium chloride crystals; 0.5-3% by weight of magnesuim stearate; 3-15% by weight of microcrystalline cellulose; 0.5-2.0% by weight cross-linked polyvinyl pyrrolidone; wherein the individual potassium chloride crystals are coated with a material comprising ethyl cellulose in an amount in the range of about 9% to about 15% by weight based on the total weight of the coated crystals and at least one member selected from hydroxypropylcellulose and polyethlene glycol in an amount in the range of about 0.5% to about 3% by weight based on the total weight of the coated crystals.